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Abstract
Background: Previous studies showed higher early mortality rates among patients treated with antiretroviral drugs in
settings with limited resources. One of the reasons was late presentation of patients to care. With improved access to HIV
services, we expect improvements in disease stage at presentation. Our objective was to assess the effect of improved
availability of HIV services on patient presentation to care and subsequent pre-ART and on-ART outcomes.
Methodology and Principal Findings: At Arba Minch Hospital in Ethiopia, we reviewed baseline characteristics and outcomes
of 2191 adult HIV patients. Nearly a half were in WHO stage III at presentation. About two-thirds of the patients (1428) started
ART. Patients enrolled in the early phase (OR=4.03, 95% CI 3.07–5.27), men (OR=1.78, 95%CI 1.47–2.16), and those aged 45
years and above (OR=2.04, 95%CI 1.48–2.82) were at higher risk of being in advanced clinical stage at presentation. The pre-
treatment mortality rate was 13.1 per 100 PYO, ranging from 1.4 in the rapid scale-up phase to 25.9 per 100 PYO in the early
phase. A quarter of the patients were lost to follow-up before starting treatment. Being in less advanced stage (HR=1.9, 95%
CI=1.6, 2.2), being in the recent cohort (HR=2.0, 95% CI=1.6, 2.6), and rural residence (HR=1.8, 95% CI=1.5, 2.2) were
independent predictors of pre-ART loss to follow-up. Of those who started ART, 13.4% were lost to follow-up and 15.4% died.
The survival improved during the study. Patients with advanced disease, men and older people had higher death rates.
Conclusions and Significance: Patients started to present at earlier stages of their illness and death has decreased among
adultHIVpatientsvisitingArbaMinchHospital.However,manypatientswere lostfrompre-treatmentfollow-up.Earlytreatment
start contributed to improved survival. Both pre-ART and on-ART patient retention mechanisms should be strengthened.
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Introduction
Early diagnosis, timely initiation of treatment, and retention in
care depend both on patient characteristics and health systems
factors. [1,2] During the early years of introduction of antiretroviral
therapy (ART) in resource-limited settings, late presentation was
inevitablebecauseoflackofaccesstoantiretroviraldrugs(ARVs).In
recent years, however, access to ARVs has improved and lack of
drugs cannot be taken as reasons for late initiation of treatment. [3]
The Ethiopian Ministry of Health (MOH) introduced ART in
2003 on subsidized, fee-based scheme, and ART became freely
available since 2005. Further, ART was decentralized to health
centres in 2006, which marked the rapid scale-up phase in the history
of the Ethiopian ART programme. [4] In addition to adopting the
WHO-recommended public health approach, Ethiopia used inno-
vative models such as a nationwide campaign to achieve national
targets both for ART and HIV testing and counselling. [5] Whether
this improved availability of HIV services has been accompanied by
earlier presentation of patients to care has not been studied.
Not all patients who present at earlier stage of their illness are
eligible for ART. Even when they are eligible for ART, prompt
initiation of treatment will depend on several factors including
availability of medicines and trained health workers. It is therefore
likely that in settings with high disease burden and limited
resources, some patients will either default from treatment or will
even die before they are started on ART. Such pre-ART patient
outcomes including death and loss rates are not adequately
documented, as most of the literature has focused on outcomes
after ART initiation. [6]
Here, we present data on stage shifting and pre-ART outcomes
from a district hospital in southern Ethiopia. Our objective was to
assess whether there had been a shift in disease stage at
presentation and determine pre-ART and on-ART patient
outcomes among patients enrolled in care over a six-year period.
Methods
Participants
We did this study at Arba Minch Hospital, located 500 Km
south of Addis Ababa. The hospital started providing ART in
August 2003 with financial support from the Norwegian Lutheran
Mission. When Ethiopia launched the ‘free’ ART programme in
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delivery. Since 2005, the MOH supplied ARVs and other HIV
related commodities. In close coordination with the routine work
and with technical support from the University of Bergen,
Norway, we set up an HIV research cohort described in detail
elsewhere. [7,8,9] Since mid-2006, the routine HIV work at the
hospital has received additional technical support from the
President’s Emergency Plan for AIDS Relief (PEPFAR) through
Johns Hopkins University, Technical Support for the Ethiopian
HIV/AIDS ART Initiative (JHU-TSEHAI).
Description of Procedures
Patients received care according to the national HIV treatment
guidelines [10,11]. We enrolled all HIV infected patients who
visited the HIV clinic on first-come first-served basis. A trained
health worker did initial evaluation and subsequent follow-up of
patients. Until CD4 testing was available in mid-2006, we had
used only clinical and total lymphocyte count (TLC) criteria for
starting treatment and follow-up.
DuringtheearlyphaseofARTinEthiopia,generic combinations
of stavudine (d4T), lamivudine (3TC), nevirapine (NVP), zidovu-
dine (ZDV/AZT), and Efavirenz (EFV) were approved for use[9].
Later, Tenofovir (TDF) was added to the arsenal of first line drugs
[10]. Second-line drugs included Didanosine (DDI), Abacavir
(ABC), TDF, and ZDV (if not used as first line regimen), Ritonavir
(RTV) and Lopinavir (LPV/r) [10].
Stavudine was given as 40 mg or 30 mg (depending on body
weight) twice daily until the last 3 months (from the study closure)
when the 40 mg became obsolete because of an increased
toxicity[11]; 3TC as 150 mg twice daily; and NVP 200 mg daily
for the first two weeks and then twice daily after that. ZDV was
given at a dose of 300 mg twice daily. The dose of EFV was
600 mg daily. TDF was given as 300 mg daily, ABC as 300 mg
twice daily and DDI as 250 mg or 400 mg (depending on body
weight) daily. Ritonavir (RTV) was used to ‘‘boost’’ LPV/r with a
dose of 100 mg/day; LPV/r was given as 3 capsules (400 mg
LPV/r and 100 mg RTV) twice daily. All drugs were given orally.
Two data clerks maintained both paper-based and electronic
records of patient information. Using a data abstraction form as a
guide, we recorded date of HIV testing, date of pre-ART
enrolment, WHO clinical stage, CD4 count, total lymphocyte
count (TLC), history of tuberculosis, pregnancy, age, sex, and
place of residence for all patients directly into an SPSS data file.
To ensure the inclusion of all relevant information in the database,
we did thorough cleaning of the data, cross-checked with the paper
records and included additional relevant variables between April
and December, 2009. One of the investigators (ZM) supervised the
cohort updating.
We defined pre-ART patient outcome as: (a) ‘still under pre-
ART care’-if patient was registered with the ART clinic of the
hospital, had regular follow-up with the clinic and was not having
follow-up at another health facility; (b) ‘lost to follow-up, ‘-if
patient did not have follow-up visit at least 30 days after the last
date of the next clinic appointment; (c) ‘put on ART’-if patient was
started on ART in the hospital clinic; (d), ‘died before starting
ART’-if patient was known to be dead as reported by treating
clinicians or community health agents; and (e), ‘transferred out’-if
patient moved to another health facility with confirmed written
documentation of transfer out.
In patients who were started on ART, we defined patients as lost
to follow up if they did not attend the hospital within the previous
30 days. For lost to follow up patients we did an ‘extended follow
up’ in 2009. ‘Extended follow up’ involved home visit or phone
call using community health agents. The community health agents
had completed high school education and received extra training
on HIV/AIDS. After each visit, they reported the status of each
patient to the data clerks.
We defined the patient status after extended follow-up as:
‘Died’: if a family member, neighbour or community leader
reported death of the patient. ‘Under follow up at another health
facility’: if the patient was on treatment at any health facility in the
region as reported by family, neighbours or community leaders.
‘Stopped treatment but alive’: if patient did not take ARVs for
more than 1 month and the patient was alive and did not get ART
elsewhere. ‘On traditional treatment’: if the patient reported that
he or she used traditional medicines instead of ART. ‘Left the
region’: if patient left the region as reported by family, neighbours
or community leaders. Unknown (‘true loss’): if no information was
available about patient.
Ethics
In this study, we included all adult [age greater than 14 yrs],
treatment-naı ¨ve patients enrolled in the cohort from January 2003
through 31 December, 2008. The AMH HIV cohort was ethically
cleared by the National Ethics Review Committee in Ethiopia.
Patients gave informed written consent for HIV testing. Some of
these patients were included in previously published prospective
studies for which informed written consent was obtained. [7,8,9]
For the additional retrospective data included in this updated
cohort, the study protocol was approved by the Ethics Committee
of Gamo Goffa Zone Health Department. Since this study was
based on retrospective data, informed consent was not feasible. To
ensure confidentiality, we excluded patient identifiers from the
final database. All patients received the standard care at the
hospital. [10,11]
Statistical methods
We used SPSS version 16 for data entry and analysis. In this
analysis, we stratified the patient enrolment period into three
phases: (i) January 2003-August 2006 (Early phase); (ii) September
2006-August 2007 (Rapid scale-up phase); and (iii) September
2007-December 2008 (Recent phase). We used this categorization
based on the chronology of Ethiopia’s ART scale-up [4] We then
compared the proportion of patients in each WHO clinical stage
for the three phases of enrolment using Chi-square for trend test.
Similarly, we compared the differences in time from HIV testing
to pre-ART enrolment (in days), and time from pre-ART
enrolment to ART initiation (in days).
To find out the risk factors for presenting at advanced disease
stage, we used the logistic regression method. In the logistic
regression analysis, we used WHO clinical stage dichotomized into
advanced (Stages III and IV combined) vs. less advanced (Stages
I&II combined) stages as the main outcome variable. Since CD4
testing wasnot available duringthe early phase, we didnot use CD4
count cut-off points in this analysis. We included age, marital status,
sex, and phase of enrolment in the final model, and reported the
results as odds ratio (OR) with 95% confidence interval (CI).
Then we estimated time to death and loss to follow-up using
Kaplan-Meier and Cox regression methods. We then calculated
the mortality and loss to follow up rates by dividing the total
number of deaths and losses by the person-year of observation
(PYO) for the three time periods mentioned above.
Results
Baseline results
Between January 2003 and 31 December 2008, we recruited and
followed 2391 patients. After excluding children and treatment-
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Figure 1). Their median age was 33 years (IQR, 26–38), 56% were
women, and 83% urban residents. Ninety (7.3%) of the women were
pregnant at presentation. Table 1 describes the baseline character-
istics of the cohort. Previous and current history of tuberculosis was
reported by 11.8% and 14.9% of the patients respectively.
The median time between HIV diagnosis and pre-ART
enrolment was 1 day (IQR, 0–4 days) with 49% of the patients
being enrolled within same day of testing. The median time from
pre-ART enrolment to ART initiation was 16 days (IQR, 5–101).
When stratified by year of enrolment, there was significant decline
in the duration of pre-ART waiting time: 125.5 days in the early
phase, 9 days in the rapid scale-up phase, and 15 days in the recent
cohort (Chi-square=120, P,0.001).
Patients with WHO stage III disease constituted 49.2%, stage II
19.4%, stage I 18.2%, stage IV 13.3% at the time of presentation
to care. The recent cohort had the largest proportion of patients in
stage II (33.9%) and the smallest in stage IV. Patients in the oldest
cohort were more likely to be in advanced clinical stage compared
with those in the recent cohort (adjusted OR=4.03, 95% CI 3.07–
5.27). Similarly, men compared to women (adjusted OR=1.78,
95%CI 1.47–2.16), those aged 45 years and above versus younger
ones (adjusted OR=2.04, 95%CI 1.48–2.82) as well had higher
risk of being in advanced WHO clinical stage. Also, being
divorced, widowed or separated as compared with being married
was associated with higher risk of being in advanced clinical stage.
Table 2 shows factors associated with being in advanced clinical
stage at presentation.
The 1428 treatment naı ¨ve patients who started ART contrib-
uted 2422.4 person years of observation (PYO). More than a half
were women (53.6%), the mean age was 34 (SD = +/28.8) years,
over a half (53.2%) were married, and most (84.7%) were from
urban areas. Baseline CD4 was available for 1037 patients (median
CD4 value 156 cells/mm
3 (IQR=81, 237), and 649 (62.5%)
patients had CD4 values less than 200 cells/mm
3. In 1288 patients
with baseline TLC, the median value was 1300 cells/mm
3
(IQR=900, 1900).
Combined CD4 and clinical stage accounted for 40.5% (578
patients) of the indications to start ART followed by TLC and
clinical stage in 29.7% (424 Patients), CD4 only in 26.2% (374
patients), and clinical stage only in 3.6% (52 patients) of patients.
Table 3 summarizes the clinical stage at the beginning of ART,
and shows that patients coming to the hospital now start treatment
earlier.
As first line regimen, 606 patients (42.4%) received d4t/3TC/
NVP and 564 patients (39.5%) received d4t/3TC/EFV. 136
patients (9.5%) received AZT/3TC/EFV, 110 patients (7.7%)
received AZT/3TC/NVP and the remaining 12 patients (0.8%)
received a TDF containing regimen.
Follow-up results
Pre-ART follow-up. Overall, 2191 patients contributed
777.8 person-years of observation (PYO). The median time
between enrolment and pre-ART outcome was 31 days (IQR,
5–130 days). The pre-ART mortality rate was 13.1 per 100 PYO
(102 deaths/777.8 PYO), with the highest mortality being during
the early phase (84 deaths/323.9 PYO=25.9 per 100 PYO) and
the lowest rate (4 deaths/287.8 PYO=1.4/100 PYO) during the
rapid scale-up phase. Some increment in mortality was seen in the
recent cohort (14 deaths/166 PYO=8.4 per 100 PYO).
In adjusted Cox- regression analyses controlling for WHO
stage, TLC, and Hgb, patients enrolled during the early phase
were more likely to die compared with those in the rapid scale-up
phase (adjusted HR=2.45, 95% CI=1.31,4.61). Also, patients in
advanced WHO stage compared to those in less advanced stage
(adjusted HR=2.8, 95% CI=1.6, 4.8) and those having TLC less
than or equal to the median value were more likely to die (adjusted
HR=1.6, 95% CI=1.01, 2.42) during the pre-ART period.
Figure 2A shows survival according to adjusted Cox-regression
analyses.
Figure 1. Cohort profile, Arba Minch Hospital, 2010. Of 2391 patients enrolled for care, 2191 were eligible for analysis. At the end of the pre-
ART follow-up period, 25% were not in care.
doi:10.1371/journal.pone.0013268.g001
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advanced WHO clinical stage (adjusted HR=1.9, 95% CI=1.6,
2.2), being in the recent cohort compared to being in early phase
(adjusted HR=2.0, 95% CI=1.6, 2.6), and being a rural resident
(adjusted HR=1.8, 95% CI=1.5, 2.2) were independent
predictors of loss to follow-up. Age, sex and marital status were
not associated with being lost to follow-up. Figure 2B shows
adjusted time to pre-ART loss for the three time periods according
to Cox-regression analysis.
On-ART follow-up. The median follow-up time was 17.7
(IQR 6.2, 31.5) months. At the end of the follow-up, 901 (63.1%)
patients were alive and under follow-up, 191 (13.4%) were lost to
follow up, 171 (12%) were transferred out, 161 (11.3%) had died,
and four (0.3%) patients had stopped treatment (Figure 1).
The loss to follow up rate was 8.2 per 100 PYO (191 patients
per 2315 PYO). Of these 191 patients, we were able to trace 143
patients (response rate of 143/191 (75%)). Of the 143 patients, 58
(40.6%) patients had died, 29 (20.3%) were under follow up at
another health institution, 20 (13.9%) had stopped treatment and
were alive, 14 (9.8%) had left the region, 13 (9.1%) used traditional
treatment, and in 9 (6.3%) patients the outcome remains
unknown. We also traced and found the four patients who
stopped treatment. Of these, one later restarted treatment, one
had died and two patients were alive but did not restart treatment.
Table 4 shows risk rates and hazard ratios of the 191 patients
registered as lost to follow up. The results show that patients starting
treatment during the rapid scale-up (HR [95%CI] =2 [1.1, 2.9])
and recent phase (HR [95%CI] =2.1[1.2, 3.8]) had increased risk
of loss tofollow-up.Patients living intowns,andthose who had drug
regimen change were less likely to default treatment.
The overall mortality rate was 9.1 per100 PYO (220 deaths per
2422.4 PYO). The survival of patients on ART improved during
the study period (Figure 3, Tables 4 and 5) and is associated with
improvement in patients starting treatment earlier (Table 3).
Higher mortality was associated with advanced clinical stage at
start of treatment (HR [95%CI] =2.4 [1.5, 4]), age over 45 years
at presentation (HR [95%CI] =1.7 [1.2, 2.4]) and men had
higher mortality rates than women (HR [95%CI] =1.4 [1.1, 1.8])
(Table 5).
Mortality varied with baseline CD4 count: 67 (10.4%) patients
with CD4 counts less than 200 cells/mm
3 died [7.9 deaths per 100
PYO] compared with 13 (2.7%) deaths in patients with CD4 count
200–350 cells/mm
3 [2.7 deaths per 100 PYO. From the 391
patients with no initial CD4 count, 79 (20.2%) died [8.6 deaths per
100 PYO].
Discussion
Patients now present themselves with less advanced disease than
during the early years, and our data suggest that earlier treatment
start is the main reason for improved survival. However, patients
in the recent cohort, rural residents and those in less advanced
disease stage were more likely to default before starting treatment.
This is in addition to the already high on-ART loss to follow-up
rate, which we confirmed in this long-term follow-up.
The high pre-ART loss to follow-up rate is a worrying
phenomenon. Of particular concern is the higher loss rate among
patients with less advanced clinical stage who are likely to be
engaged in risky sexual practices. Part of the underlying reasons
for the high rate of loss among patients with less advanced disease
stage could be lack of means for engaging them in care. Such
patients often do not need treatment and prophylaxis for
opportunistic infections. Prophylactic interventions such as
isoniazid preventive therapy (IPT) are not widely implemented
in the study setting, as is elsewhere in Ethiopia. Also, there was no
mechanism for pre-ART patient tracing.
There is limited data on trends in immune status at presentation
among patients followed in settings with limited resources. In a
cohort followed in a well-resourced setting in the US, there was no
improvement in immune status at presentation after 16 years of
follow-up. [12] Similar to our finding, however, there was decrease
in time from HIV diagnosis to presentation for care.
High rates of pre-ART mortality and loss to care were reported
from South Africa, Uganda, and Cambodia. [13,14,15,16,17,18]
In a South African cohort, a pre-treatment mortality rate of 33.3
per 100 PYO was reported. Pre-treatment and early treatment
deaths accounted for 87% of all deaths. [20] Among Ugandan
cohort of HIV patients, pre-ART mortality rate of 27 per 100
PYO was reported. [13] An overall pre-ART mortality rate of 13.1
per 100 PYO in our cohort is much lower than the reports from
the aforementioned studies. However, when stratified by year of
Table 1. Baseline characteristics of all treatment-naı ¨ve adult














Below primary education 640 (28.2)
Primary education 711 (32.5)














Early phase 509 (23.2)
Rapid scale-up phase 1015 (46.3)
Recent phase 667 (30.4)
doi:10.1371/journal.pone.0013268.t001
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cohort is comparable to other studies.
There are explanations for the higher mortality rate among the
oldest cohort. Between January 2003 and August 2003, patients
were followed without ART as there was none in the country.
Ethiopia did not have a policy on ARV drug use until July 2002.
[19] Even when ART was made available, it took some time until
decision was made as to which patients would be prioritized. Also,
the improved clinical mentoring approach used by JHU-TSEHAI
coupled with the improved experience gained by the clinicians
could have contributed to the improved patient outcomes at later
dates.
Pre-ART loss to follow-up is a common but less clearly defined
challenge in settings with limited resources. [13,14,15,16] At a
partly private clinic in Durban, South Africa, 16.4% of the patients
were lost within three months’ of follow-up before ART initiation.
[15] In their report, having low CD4 count was associated with
being lost to follow-up, and over a third of them were found to be
dead. The higher loss rate among patients with low CD4 count is
in sharp contrast to our finding of higher loss rate among patients
with better immune status. This could be explained by the
difference in the approach used by the two settings.
In Uganda, inadequate post-test counselling and competition
from holistic and less stigmatizing traditional/spiritual healers
were cited as the main reasons for pre-ART loss. [20] Also,
transportation costs, long waiting time, lack of incentives to seek
pre-ART care by healthy looking patients and gender inequalities
were mentioned as some of the perceived reasons for the high loss.
Our on-ART loss to follow up rates are high, but comparable to
findings from 10 African and Asian countries reported in a recent
meta-analysis [21]. About 40% of the patients lost to follow up
were later found to have died, and this figure is also comparable
with meta analysis reported by Brinkhof and colleagues [21].
In our study about 20% of those lost to follow up were found to
be receiving care in another health institution, suggesting that self-
transfer of patients to ART centres of their preference is common.
There is a need for strengthening communication between health
institutions.
The on-ART mortality rate (9.1 per 100 PYO) in our study is
higher than rates from China (5.9 per100 PYO) [22], but similar
to a recent review from four African countries (mortality rate 8 per
100 PYO)[23]. A Ugandan study showed lower mortality rates
(3.5 per 100 PYO) [24], probably because more Ugandan patients
were in WHO stage II (63% compared with 43% in our study).
As expected, we found that patients with advanced clinical
disease or low CD4 count have higher risk of mortality. Possible
causes of higher mortality rates among the older patients could be
because older patients respond poorly to ART and experience more
rapid clinical progression. Older patients are also at a higher risk of
complications such as cancer and cardiovascular disease because of
the combined effect of ageing, HIV infection and antiretroviral
treatment [25]. However, there is limited data from Africa trying to
explain higher mortality rates among the older people. Although we
controlled for possible confounders such as WHO stage, age, CD4,
TLCand homeplace,menhadhigherriskofdeath,asalsoreported
from four African countries [23] and cohort studies in Europe and
North America [26]], but not from Spain[27]. Possible reasons for
higher mortality among males needs further study.
In conclusion, patients visiting Arba Minch Hospital for HIV
treatment have started to present at less advanced disease stages.
This was accompanied by a decline in patient mortality rate.
Table 2. Logistic regression analysis of factors associated with being in advanced WHO clinical stage (WHO stage III&IV) for all
patients, Arba Minch Hospital, 2010.
Predicator variable Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
Phase of enrollment
Recent phase 1.00 1.00
Rapid scale-up phase 2.23 (1.82–2.72) ,0.001 2.12 (1.73–2.61) ,0.001
Early phase 4.16 (3.21–5.39) ,0.001 4.03 (3.07–5.27) ,0.001
Marital status
Married 1.00 1.00
Unmarried 1.23 (0.96–1.58) .0.1 1.15 (0.88–1.51) .0.05
Divorced, widowed or separated 1.34 (1.15–1.71) ,0.01 1.38 (1.11–1.71) ,0.01
Sex
Female 1.00 1.00
Male 1.81 (1.51–2.16) ,0.001 1.78 (1.47–2.16) ,0.001
Age in years
15–44 1.00 1.00
45+ 2.34 (1.73–3.17) ,0.001 2.04 (1.48–2.82) ,0.001
doi:10.1371/journal.pone.0013268.t002
Table 3. WHO clinical stage at start of antiretroviral treatment









Early 14 (6.3) 209 (93.7) 223 (100)
Rapid-scale up 135 (17.3) 646 (82.7) 781 (100)
Recent 148 (34.9) 276 (65.1) 424 (100)
Total 297 (20.8) 1131 (79.2) 1428 (100)
Chi–square for trend (X
2=83.3; df =1; P,0.001).
doi:10.1371/journal.pone.0013268.t003
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PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13268Figure 2. Survival curve according to Cox regression analysis after adjusting for disease stage, age and place of residence, Arba
Minch Hospital, 2010. At about 48 weeks of pre-ART follow-up, about 25% of patients in the ‘early phase’ were not alive (See 2A). On the other
hand, over 95% of those in the ‘rapid scale-up’ phase were alive at 48 weeks. Pre-ART loss to follow-up was less in the ‘early phase’ (See 2B).
doi:10.1371/journal.pone.0013268.g002
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13268Figure 3. Kaplan –Meier (3 A) and Cox-proportional hazard’s (3 B) survival plots according to the three periods of ART initiation,
Arba Minch Hospital, 2010.
doi:10.1371/journal.pone.0013268.g003
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,=45 2097.2 175 8.3 1 1
.45 217.8 16 7.3 0.9 [0.5,1.5] 0.9 [0.5,1.5]
Address
Rural 233.4 47 20.1 1 1
Urban 2081.6 144 6.9 0.3 [0.2,0.5] 0.5 [0.3,0.6]
Gender
Female 1253.1 104 8.3 1 1
Male 1061.9 87 8.2 0.9 [0.7,1.3] 0.9 [0.7,1.3]
Phase of ART initiation
Early 584.6 17 3 1 1
Rapid scale-up 1448.4 125 8.6 2.9 [1.8,5.1] 2 [1.1,2.9]
Recent 282 49 17.4 5.9 [3.5,10.6] 2.1 [1.2,3.8]
WHO stage
I and II 392.8 32 8.1 1 1
III and IV 1922.2 159 8.3 1.1 [0.7,1.5] 1.2 [0.9,1.9]
Change of drug regimen
Yes 598.8 15 2.5 0.2 [0.1,0.4] 0.4 [0.2,0.6]
No 1716.2 176 10.3 1 1
CI= Confidence Interval, HR= Hazard ratio, Person Years of Observation.
doi:10.1371/journal.pone.0013268.t004













,=45 2203.2 186 8.4 1
.45 219.2 34 15.5 1.8 [1.3,2.6] 1.7 [1.2,2.4]
Address
Rural 234.2 27 11.5 1 1
Urban 2188.2 193 8.8 0.8 [0.5,1.2] 0.9 [0.6,1.5]
Gender
Female 1319.1 94 7.1 1
Male 1103.3 126 11.4 1.6 [1.2,2.1] 1.4 [1.1,1.8]
Phase of ART initiation
Early 608.4 62 10.2 1 1
Rapid scale-up 1522.3 130 8.5 0.8 [0.6,1.1] 0.5 [0.4,0.7]
Recent 291.7 28 9.6 0.9 [0.6,1.5] 0.4 [0.2,0.6]
WHO stage
I and II 412.1 17 4.1 1 1
III and IV 2010.3 203 10.1 2.4 [1.5,4.1] 2.4 [1.5,4]
Change of drug regimen
No 1815.6 186 10.2 1
Yes 606.8 34 5.6 0.5 [0.4–0.8] 0.5 [0.4,0.8]
CI= Confidence Interval, HR= Hazard ratio, PYO= Person Years of Observation.
doi:10.1371/journal.pone.0013268.t005
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PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13268However, high rate of pre-ART loss to follow up especially among
well-looking and rural patients appears to be a growing challenge.
This suggests the need for strengthening the pre-ART phase of
HIV care. Also, we documented high rate of loss to follow up of
patients on ART. Thus, there is an urgent need to enhance the
community tracing of patients defaulting. The country now uses
adherence supporters (most of whom are PLHIV) as adherence
counsellors and defaulter tracers.
Health care workers in similar settings should pay more attention
to clients who are likely to default during the pre-ART phase. More
targeted counselling and follow-up is needed. Also, existing
interventions such as IPT and management of other opportunistic
infections could be used as incentives to engage patients in care.
[28,29] There is a need for clear policy on pre-ART patient care
including the intensity of follow up and monitoring and evaluation
tools. Definitions for pre-ART loss should be standardized. The
human resource implications, cost and cost-effectiveness of
instituting pre-ART care package should be studied.
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